Alumis Inc., a clinical-stage biopharmaceutical company, announced an update on its merger agreement with ACELYRIN, Inc. On May 13, 2025, Alumis stockholders approved all proposals related to the pending merger during a Special Meeting of Stockholders. The merger, slated for completion in the second quarter of 2025, aims to enhance value creation opportunities for both companies' stockholders. The amended agreement stipulates that ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock per ACELYRIN share. Post-merger, Alumis stockholders will hold approximately 52% of the combined entity, while ACELYRIN stockholders will own around 48% on a fully diluted basis. The merger is expected to advance a differentiated clinical pipeline and provide financial flexibility for strategic opportunities in immune-mediated diseases.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。